MEMBRANOUS NEPHROPATHY

This observational study follows 500 adults with primary membranous nephropathy and nephrotic syndrome who are treated with rituximab or similar antibody drugs. Researchers will track how well the disease responds over time and what factors predict better outcomes. The goal is to…

This study tests whether an artificial intelligence program can help doctors give the right dose of the drug rituximab to people with a kidney disease called membranous nephropathy. The disease causes the immune system to attack the kidneys, and rituximab helps calm that attack. …

This study tests whether adding belimumab to rituximab works better than rituximab alone for people with membranous nephropathy, a kidney disease that causes protein leakage. About 58 adults will receive either the combo or rituximab alone, and researchers will check if their kid…

This study tests a new drug (HLX79) combined with an existing antibody treatment (rituximab) in people with active kidney inflammation called glomerulonephritis. The goal is to see if the combination is safe and helps control the disease better than rituximab alone. About 24 adul…

This study looks at blood cells from 86 people with membranous nephropathy, a kidney disease, to find out why some get better with B-cell therapy and others don't. Researchers will compare immune cells in patients who respond to treatment, those who don't, and healthy volunteers.…

This study helps people with nephrotic syndrome and related kidney diseases find clinical trials that may be a good fit for their specific condition. Researchers use detailed molecular information from each participant to recommend targeted therapies being tested in other studies…

This study interviews 150 children, adults, and parents about their experiences with swelling caused by Nephrotic Syndrome. Researchers will use the information to create a survey that helps test new medications. No treatment is given; the goal is to better understand symptoms.